102877-36-1

Basic information

• Product Name: 1,2-Propanediol, 3-(4-chlorophenyl)-
• CAS NO: 102877-36-1
• Molecular Formula: C9H11ClO2
• Molecular Weight: 186.638
• Mol File: 102877-36-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,2-Propanediol, 3-(4-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Propanediol, 3-(4-chlorophenyl)-(102877-36-1)
• EPA Substance Registry System: 1,2-Propanediol, 3-(4-chlorophenyl)-(102877-36-1)

Safety Data

• Hazardous Substances Data: 102877-36-1(Hazardous Substances Data)

Usage

Appearance

Pale yellow to off-white solid

Usage

Primary intermediate in the manufacture of pharmaceuticals and other organic compounds

Applications

Building block for the synthesis of various medications (e.g. antihistamines and local anesthetics), production of fragrance and flavoring compounds, synthesis of specialty chemicals, potential use as a solvent and chemical reagent in laboratory settings.

Upstream product

• 79-21-0 peracetic acid 
• 1745-18-2 1-allyl-4-chlorobenzene 
• 80540-56-3 methyl 3-(4-chlorophenyl)-2-hydroxyacrylate 
• 93634-55-0 2-methyl-4-(4-chlorobenzylidene)-4H-oxazol-5-one 
• 127273-12-5 3-(4-chlorophenyl)-2-hydroxyacrylic acid 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 68685-70-1 1-[4-(4-chloro-benzyl)-2-(2,4-dichloro-phenyl)-[1,3]dioxolan-2-ylmethyl]-1H-imidazole 
• 79146-75-1 2-Bromomethyl-4-(4-chloro-benzyl)-2-(2,4-dichloro-phenyl)-[1,3]dioxolane 

Relevant articles and documents

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.